Global reemergence of tuberculosis: are host defense peptides an option to ameliorate disease burden?
Tuberculosis is the most relevant infectious disease worldwide according to the estimates of the World Health Organization, and despite being a curable disease, it requires a 6-9-month therapy with multiple antibiotics. Intermittent drug therapy due to noncompliance or poor delivery of therapy promotes the emergence of bacterial strains showing resistance to multiple drugs and the rise of extremely drug-resistant strains. Moreover, increased antibiotic resistance has been observed for several microorganisms, including extremely drug-resistant tuberculosis, vancomycin-resistant Enterococcus faecalis, or methicillin-resistant Staphylococcus aureus. In vitro, cathelicidin induction results in enhanced mycobacterial clearance, and synthetic human neutrophil peptides had a rather modest bactericidal effect in Mycobacterium tuberculosis-infected mice. In vivo therapeutic efficacy of improved molecules that show enhanced bactericidal action in vitro remains to be tested.
Flores-Valdez
Mario Alberto
MA
Biomedical Biotechnology, Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C., Guadalajara, Mexico. floresv@ciatej.net.mx
Chopra
Sidharth
S
D000818:Animals; D000890:Anti-Infective Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D054804:Cathelicidins / Q000138:chemical synthesis / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D014943:Global Health; D006801:Humans; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology
D000890:Anti-Infective Agents; D054804:Cathelicidins